HCM
RNTX

Highbridge Capital Management’s Rein Therapeutics RNTX Stock Holding History

Highbridge Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,522
Closed -$562K – 1826
2017
Q2 		$562K Buy
+2,522
New +$554K 0.01% 721

Other funds holding RNTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Highbridge Capital Management's RNTX Position: Q3 2017 in Review

Highbridge Capital Management sold out of Rein Therapeutics (RNTX) in Q3 2017, closing a stake of 2,522 shares — an estimated $562K sold.

Highbridge Capital Management first reported a position in RNTX in Q2 2017 and held it in 1 quarter. The position peaked at $562K in Q2 2017. 31 funds tracked by Wall St. Rank hold RNTX as of Q3 2017.

  • Highbridge Capital Management reported no remaining Rein Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 2,522 Rein Therapeutics shares in Q3 2017, an estimated $562K.
  • Highbridge Capital Management first reported a position in Rein Therapeutics in Q2 2017 and held it in 1 quarter.
  • Highbridge Capital Management's Rein Therapeutics position peaked at $562K in Q2 2017.
  • 31 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.